Skip to main content
    I

    Iovance Biotherapeutics Inc (IOVA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $14.72
    +0.51 (+3.59%)

    Market Cap: $6.50B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    44%(17/39)
    Avg Surprise
    -3.01%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.10 - $-0.07
    8 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.12+30.6%
    60d ago$-0.09+2.8%
    30d ago$-0.10+10.0%
    7d ago$-0.090.0%
    Current$-0.09
    Revenue Consensus
    $114M
    Range$108M - $118M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.08
    Range$-0.13 - $-0.03
    8 analysts
    Revenue Consensus
    $132M
    Range$115M - $138M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.08---
    Sep 26EST
    		-$-0.09---
    Jun 26
    Reported Aug 6
    		$-0.11$-0.17+35.29%Beat+66.7%
    Mar 26
    Reported May 7
    		$-0.19$-0.15-23.78%Miss+47.2%
    Dec 25
    Reported Feb 24
    		$-0.18$-0.18+0.00%Beat+30.8%
    Sep 25
    Reported Nov 6
    		$-0.25$-0.26+3.85%Beat+10.7%
    Jun 25
    Reported Aug 7
    		$-0.33$-0.29-13.79%Miss+2.9%
    Mar 25
    Reported May 8
    		$-0.36$-0.24-50.00%Miss+14.3%
    Dec 24
    Reported Feb 27
    		$-0.26$-0.27+2.84%Beat+42.2%
    Sep 24
    Reported Nov 7
    		$-0.28$-0.30+6.67%Beat+39.1%
    Jun 24
    Reported Aug 8
    		$-0.34$-0.35+2.86%Beat+27.7%
    Mar 24
    Reported May 9
    		$-0.42$-0.42+0.00%Beat+16.0%
    Dec 23
    Reported Feb 28
    		$-0.45$-0.43-4.65%Miss+29.7%
    Sep 23
    Reported Nov 7
    		$-0.46$-0.46+0.00%Beat+27.0%
    Jun 23
    Reported Aug 8
    		$-0.47$-0.79+40.51%Beat+25.4%
    Mar 23
    Reported May 9
    		$-0.50$-0.73+31.51%Beat+13.8%
    Dec 22
    Reported Feb 28
    		$-0.64$-0.64+0.00%Beat-1.6%
    Sep 22
    Reported Nov 3
    		$-0.63$-0.64+1.56%Beat-14.5%
    Jun 22
    Reported Aug 4
    		$-0.63$-0.61-3.28%Miss-18.9%
    Mar 22
    Reported May 5
    		$-0.58$-0.63+7.94%Beat-13.7%
    Dec 21
    Reported Feb 24
    		$-0.63$-0.56-12.50%Miss-34.0%
    Sep 21
    Reported Nov 4
    		$-0.55$-0.53-3.77%Miss-37.5%
    Jun 21
    Reported Aug 5
    		$-0.53$-0.51-3.92%Miss-12.8%
    Mar 21
    Reported May 6
    		$-0.51$-0.49-4.08%Miss+7.3%
    Dec 20
    Reported Feb 25
    		$-0.47$-0.44-6.82%Miss+6.0%
    Sep 20
    Reported Nov 5
    		$-0.40$-0.46+13.04%Beat+0.0%
    Jun 20
    Reported Aug 6
    		$-0.47$-0.52+9.62%Beat-23.7%
    Mar 20
    Reported May 5
    		$-0.55$-0.51-7.84%Miss-83.3%
    Dec 19
    Reported Feb 25
    		$-0.50$-0.42-19.05%Miss-85.2%
    Sep 19
    Reported Nov 4
    		$-0.40$-0.39-2.56%Miss-11.1%
    Jun 19
    Reported Aug 1
    		$-0.38$-0.29-31.03%Miss-11.8%
    Mar 19
    Reported May 7
    		$-0.30$-0.29-3.45%Miss+3.2%
    Dec 18
    Reported Feb 27
    		$-0.27$-0.26-3.85%Miss+15.6%
    Sep 18
    Reported Nov 6
    		$-0.36$-0.33-9.09%Miss-2.9%
    Jun 18
    Reported Aug 6
    		$-0.34$-0.32-6.25%Miss+8.1%
    Mar 18
    Reported May 10
    		$-0.31$-0.29-6.90%Miss-10.7%
    Dec 17
    Reported Mar 12
    		$-0.32$-0.32+0.00%Beat-28.0%
    Sep 17
    Reported Oct 31
    		$-0.35$-0.29-20.69%Miss-
    Jun 17
    Reported Aug 1
    		$-0.37$-0.28-32.14%Miss-
    Mar 17
    Reported May 1
    		$-0.28$-0.27-3.70%Miss-
    Dec 16
    Reported Mar 7
    		$-0.25$-0.25+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-20.16EV/EBITDAN/A
    Price/FCF-22.36xFCF Yield-4.47%
    Profitability
    Profit Margin-89.10%Operating Margin-52.30%
    ROE-40.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio4.35xQuick Ratio3.82x
    Trading Statistics
    Beta0.76Avg Volume18.37M
    52-Week High$15.3052-Week Low$1.76

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$14.02
    SMA 20$12.89
    SMA 50$9.97
    SMA 200$5.24
    EMA 10$13.95
    EMA 20$12.92
    EMA 50$10.48
    EMA 200$6.25

    MACD

    Line: 1.42Signal: 1.44Hist: -0.02

    ADX

    ADX: 56.1+DI: 35.1-DI: 15.4

    Aroon & PSAR

    Aroon Up52.0
    Aroon DownN/A
    PSAR$14.96

    Bollinger Bands

    Upper Band$16.53
    Lower Band$9.24
    %B Position5657%(Upper)
    Band Width0.75

    RSI (14-Day)

    Overbought
    71.0

    Momentum Oscillators

    Stoch %K82.8
    Stoch %D83.6
    Williams %R-12.6
    ROC (10d)3.4%
    Momentum0.49
    CCI (20d)65.0
    MFI (14d)69.0

    Volatility Measures

    ATR (14d)$0.85(5.7%)
    StdDev (20d)1.82
    Hist Vol125.8%(High)

    Volume Flow

    VWAP$14.42
    OBV346.4M
    AD Line-108.8M
    CMF (20d)0.182

    Volume Metrics

    Avg Vol (20d)18.0M
    Vol Ratio0.6x
    VWMA (20d)$13.14

    Pivot Points

    R3$15.01
    R2$14.82
    R1$14.52
    Pivot Point$14.33
    S1$14.03
    S2$13.84
    S3$13.54

    Advanced Oscillators

    TSI44.32
    Ultimate Osc67.2
    KST568.47

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$99.31M$71.43M$86.77M$67.45M$59.95M$49.32M$73.69M$58.55M$31.11M$715,000$482,000$469,000
    Cost of Revenue$43.59M$42.50M$28.30M$38.48M$48.88M$42.72M$23.10M$31.52M$31.37M$7.26M$-5,357,000$4.34M
    Gross Profit$55.72M$28.93M$58.47M$28.98M$11.07M$6.61M$50.59M$27.04M$-262,000$-6,546,000$5.84M$-3,871,000
    Operating Expenses$107.62M$109.97M$131.93M$123.88M$124.84M$127.83M$137.17M$116.10M$101.65M$111.18M$127.09M$114.49M
    R&D$58.85M$62.49M$68.85M$75.17M$77.93M$75.97M$67.33M$67.04M$62.08M$79.78M$76.59M$87.53M
    SG&A$39.27M$38.95M$36.14M$34.55M$37.57M$43.80M$41.97M$39.34M$39.57M$31.39M$29.09M$26.96M
    Operating Income$-51,905,000$-81,043,000$-73,460,000$-94,901,000$-113,774,000$-121,221,000$-86,576,000$-89,066,000$-101,914,000$-117,722,000$-121,256,000$-118,361,000
    Interest Income$3.22M$1.33M$1.74M$1.24M$4.10M$3.22M$9.57M$4.00M$3.35M$3.34M$3.12M$3.36M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-48,688,000$-79,710,000$-71,720,000$-93,658,000$-109,670,000$-118,001,000$-77,001,000$-85,061,000$-98,559,000$-114,384,000$-118,138,000$-115,003,000
    Income Tax Expense$-1,373,000$-665,000$184,000$-2,405,000$1.99M$-1,838,000$1.56M$-1,520,000$-1,458,000$-1,408,000$-1,759,000$-1,243,000
    Net Income$-47,315,000$-79,045,000$-71,904,000$-91,253,000$-111,658,000$-116,163,000$-78,559,000$-83,541,000$-97,101,000$-112,976,000$-116,379,000$-113,760,000
    EBITDA$-42,916,000$-71,748,000$-62,158,000$-84,935,000$-103,550,000$-112,432,000$-72,184,000$-81,585,000$-93,549,000$-110,150,000$-113,269,000$-109,509,000
    EBIT$-51,905,000$-81,043,000$-73,460,000$-94,901,000$-113,774,000$-121,221,000$-86,576,000$-89,066,000$-101,914,000$-117,722,000$-121,256,000$-118,361,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IOVA

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    1
    Avg Remaining Term
    N/A

    Recent Awards

    Award IDAgencyObligatedStart
    36C24826N0268Department of Veterans AffairsDepartment of Veterans Affairs$0Jan 5, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Sep 30, 2026.

    News

    Barclays lifts target for Iovance Biotherapeutics stock to USD 18.00

    Barclays has increased its price target for Iovance Biotherapeutics (IOVA) to USD 18.00 from USD 15.00, while the average analyst target from 13 firms stands at USD 13.20. The company reported a 65.70% increase...

    ad-hoc-news.de•10/15/26•Bullish

    Why Is IOVA Stock Falling Today?

    Iovance (IOVA) stock plunged 15% following a first-quarter report that missed Wall Street revenue and earnings estimates. The company also faces investor concerns due to mounting delays in securing U.K. and European...

    Stocktwits•10/14/26•Bearish

    Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $18

    Barclays has reiterated its Buy rating for Iovance Biotherapeutics (IOVA.US) and increased its target price for the stock from $17 to $18. This adjustment indicates a continued positive outlook on the company's financial...

    Moomoo•10/14/26•Bullish

    IOVA Maintained by Barclays -- Price Target Raised to $18.00

    Barclays has reiterated an "Overweight" rating for Iovance Biotherapeutics (IOVA) and increased its price target from $15.00 to $18.00...

    GuruFocus•10/13/26•Somewhat-Bullish

    ETFs Investing in Iovance Biotherapeutics Inc Stocks

    This article lists various Exchange Traded Funds (ETFs) that hold shares of Iovance Biotherapeutics Inc. The information provided for each ETF includes market value, weight of Iovance stock, issuer, management style...

    TradingView•10/12/26•Neutral

    IOVA Valuation and Fair Value

    P/E
    -20.2x
    P/FCF
    -22.4x
    PEG
    0.0x
    P/B
    9.0x
    See GNG's fair value

    IOVA Profitability: Margins, ROIC and FCF

    Gross margin
    53.0%
    Operating margin
    -52.3%
    Net margin
    -89.1%
    ROE
    -40.4%
    FCF margin
    -91.2%
    FCF yield
    -4.5%

    IOVA Competitors

    CompanyTicker
    Lantheus Holdings IncLNTH
    GRAIL, LLCGRAL
    Amneal Pharmaceuticals, Inc. Class A Common StockAMRX
    Centessa Pharmaceuticals PLC ADRCNTA
    Praxis Precision Medicines IncPRAX
    Kiniksa Pharmaceuticals LtdKNSA
    Merus BVMRUS
    Rhythm Pharmaceuticals IncRYTM

    Sector: Healthcare

    IOVA Analyst Ratings

    Consensus
    Buy
    Analysts
    10
    Strong Buy
    2
    Buy
    6
    Hold
    2
    Sell
    0
    Strong Sell
    0

    IOVA Bull Case vs Bear Case

    Bull case

    • IOVA grew quarterly revenue 65.7% year over year.
    • 80.0% of IOVA's analyst ratings are Buy or Strong Buy.

    Bear case

    • IOVA has a -89.1% net profit margin.

    IOVA Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -4.9%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.09
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 1 down

    Frequently Asked Questions About IOVA

    Does IOVA pay dividends?

    Iovance Biotherapeutics Inc (IOVA) does not currently pay a regular dividend.

    What is IOVA's market cap?

    Iovance Biotherapeutics Inc (IOVA) has a market capitalization of $6.50B with a current stock price of $14.72.

    Related stocks

    Sector: Healthcare

    All stocks starting with I

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In